This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AngioDynamicis' (ANGO) Solero MTA System to Drive Growth
by Zacks Equity Research
Growth in the core Angiographic Catheter business is also likely to fortify the company's footprint in the global space.
Integra Closes Codman Buyout, Strengthens Neurosurgery Arm
by Zacks Equity Research
With Codman's acquisition by Integra (IART), the neurosurgery business is likely to drive the company's 2018 adjusted earnings per share with a minimum yield of 22 cents.
Amedisys' Arm Buys Intercity Home Care, Boosts U.S. Base
by Zacks Equity Research
Amedisys' (AMED) encouraging efforts put the Personal Care business on growth track. This segment lives up to a strong performance with the integration of several recent tuck-in acquisitions.
Boston Scientific's Apama Deal to Boost Electrophysiology Arm
by Zacks Equity Research
Boston Scientific's (BSX) Apama Medical addition is expected to strengthen its suite of arrhythmia solutions under the Electrophysiology sub-segment.
Quest Diagnostics Buys 2 Outreach Labs, Widens Customer Base
by Zacks Equity Research
Quest Diagnostics (DGX) completes acquisition of outreach laboratory services of two Hartford HealthCare hospitals. The deal is expected to widen the network of the company.
Abbott to Gain from Alere's Takeover Due for Oct 3 Closure
by Zacks Equity Research
Alere's acquisition would help Abbott (ABT) explore new channels and geographies, including forays into fast growing outlets like doctors' offices, clinics, pharmacies and at-home testing.
AngioDynamics (ANGO) Misses on Earnings & Revenues in Q1
by Zacks Equity Research
AngioDynamics' (ANGO) adjusted gross margin decreased year over year owing to voluntary market withdrawal of the Acculis Microwave Tissue Ablation System.
Masimo RAS-45 Full-Market Release to Boost Respiratory Care
by Zacks Equity Research
Masimo Corporation's (MASI) newly launched RAS-45, a single use adhesive respiration sensor would strengthen the company's foothold in the growing global respiratory care market.
Baxter Announces Launch of DeviceVue System for Sigma Pumps
by Zacks Equity Research
Baxter's (BAX) latest development is expected to fortify its foothold in the smart pumps market.
Here's Why Mazor Robotics (MZOR) Stock Is Worth a Bet Now
by Zacks Equity Research
The market is upbeat about Mazor Robotics' (MZOR) recent CE Mark approval for Mazor X Surgical Assurance platform.
STERIS (STE) Rides on Organic Growth, Stiff Contest a Threat
by Zacks Equity Research
STERIS' (STE) consistent strong organic all-segment growth performance impresses investors. Additionally, growth in free cash flow reserve denotes the company's solid cash position.
Here's Why You Should Invest in Orthofix International Now
by Zacks Equity Research
Orthofix (OFIX) rides high on strength in Biologics and Spine Fixation.
Allscripts Rides High on Product Launches Amid Rising Costs
by Zacks Equity Research
Management at Allscripts Healthcare (MDRX) is focused on various restructuring initiatives, research and development plans and launch of exclusive products.
Omnicell (OMCL) Gains on Product Launches, Global Expansion
by Zacks Equity Research
The market is upbeat about Omnicell's (OMCL) recently-launched XT Series Automated Supply Dispensing Cabinet. The company is also expanding its footprint globally.
Align Technology (ALGN) Prospects Bright, Competition Rife
by Zacks Equity Research
Align Technology (ALGN) continues to gain from strong InvisAlign sales amid macroeconomic headwinds.
Cerner (CERN) Banks on RCM & PH Platforms, Competition Rife
by Zacks Equity Research
Cerner's (CERN) stable position provides solid growth opportunities in the revenue cycle management (RCM) suite of solutions.
PetMed Express Optimistic on New Orders Amid Stiff Rivalry
by Zacks Equity Research
PetMed is striving to implement several strategies to revitalize its top line. Yet a highly competitive market poses threats.
Here's Why Investors Should Buy Masimo (MASI) Right Now
by Zacks Equity Research
Masimo (MASI) announced 510(k) clearance and full-market release of its proprietary Rad-97 Pulse CO-Oximeter earlier this month.
Amedisys or Chemed: Which is a Better Investment Choice?
by Zacks Equity Research
After considering various parameters and fundamentals, we help you make a choice between Amedisys (AMED) and Chemed (CHE).
Why Should Investors Add Amedisys (AMED) to Their Portfolio?
by Zacks Equity Research
Amedisys (AMED) rides high on solid prospects with new opportunities within home health and hospice services segments.
Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now
by Zacks Equity Research
IDEXX Laboratories (IDXX) continues to boost investor's confidence with strong companion animal business along with balanced growth across all segments.
Why is Edwards Lifesciences (EW) a Strong Buy Stock Now?
by Zacks Equity Research
Several recent FDA product-approvals boost investors' trust in Edwards Lifesciences' (EW) stock.
Here's Why You Should Add Chemed (CHE) to Your Portfolio
by Zacks Equity Research
Chemed (CHE) bolsters investor's confidence with continued strength in Roto-Rooter business.
Here's Why You Should Bet on BioTelemetry (BEAT) Stock Now
by Zacks Equity Research
BioTelemetry's (BEAT) consistent efforts in product innovation through research and development buoy optimism. Also, the recent acquisition instills confidence in investors.
BD (BDX) Inks New Deal to Strengthen Foothold in STI Space
by Zacks Equity Research
BD (BDX) is a leading player in providing solutions for women's health and sexually transmitted infections. Its latest development is likely to lend the company a competitive edge in the niche space.